BioElectronics' Topical Pain Therapy Now Available Throughout Europe

Published on Tuesday, 21 August 2012 05:09 Written by TradersHuddle Staff

-- ActiPatch Musculoskeletal Pain Therapy is Five Times Better Than OTC Drugs --

FREDERICK, Md., Aug. 21, 2012 /PRNewswire/ -- BioElectronics Corporation (BIEL), maker of patented, inexpensive, disposable pain management devices, said today that ActiPatch® Musculoskeletal Pain Therapy is now available for purchase on Amazon.co.uk in 27 European countries.  Visit www.actipatchrelief.co.uk to place an order in Europe.

"ActiPatch® has five times better pain relief and is 100% safer than over-the-counter drugs.  The most commonly used OTC drugs have a significant number of side effects, are minimally effective and have only short-term relief.  ActiPatch, which retails for €14.99 to €19.99 for 90 8-hour treatments or under €.25 each, is the sound utilization of advanced technology to lower the cost of healthcare and to provide sustained pain relief," said Andrew Whelan, President.

The countries covered in the sales and distribution agreement are the United Kingdom, Germany, France, Spain, Italy, Belgium, Luxembourg, Netherlands, Ireland, Portugal, Austria, Bulgaria, Cyprus, the Czech Republic, Denmark, Estonia, Finland, Greece, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia, Slovenia and Sweden.

About BioElectronics Corporation

BioElectronics is an award winning developer and manufacturer of advanced medical devices. Its products are ActiPatch® Therapy, for over-the-counter treatment of back pain and other musculoskeletal ailments, the Allay™ Menstrual Cycle Pain Therapy, and RecoveryRx™ for surgical procedures and wound care. The unique therapy delivery system, using patented technology, provides a cost-effective home care to reduce soft tissue pain and accelerate healing. For more information, please visit www.BielCorp.com.

Contact:

Paul Knopick

940.262.3584

This e-mail address is being protected from spambots. You need JavaScript enabled to view it.

SOURCE BioElectronics Corporation